584 related articles for article (PubMed ID: 25352327)
1. Causality assessment for suspected DILI during clinical phases of drug development.
Regev A; Seeff LB; Merz M; Ormarsdottir S; Aithal GP; Gallivan J; Watkins PB
Drug Saf; 2014 Nov; 37 Suppl 1(Suppl 1):S47-56. PubMed ID: 25352327
[TBL] [Abstract][Full Text] [Related]
2. Liver safety assessment: required data elements and best practices for data collection and standardization in clinical trials.
Avigan MI; Bjornsson ES; Pasanen M; Cooper C; Andrade RJ; Watkins PB; Lewis JH; Merz M
Drug Saf; 2014 Nov; 37 Suppl 1(Suppl 1):S19-31. PubMed ID: 25352325
[TBL] [Abstract][Full Text] [Related]
3. Top-ranking drugs out of 3312 drug-induced liver injury cases evaluated by the Roussel Uclaf Causality Assessment Method.
Teschke R
Expert Opin Drug Metab Toxicol; 2018 Nov; 14(11):1169-1187. PubMed ID: 30354694
[TBL] [Abstract][Full Text] [Related]
4. Drug-Induced Liver Injury: Why is the Roussel Uclaf Causality Assessment Method (RUCAM) Still Used 25 Years After Its Launch?
Danan G; Teschke R
Drug Saf; 2018 Aug; 41(8):735-743. PubMed ID: 29502198
[TBL] [Abstract][Full Text] [Related]
5. Assessment of drug-induced liver injury in clinical practice.
Lucena MI; García-Cortés M; Cueto R; Lopez-Duran J; Andrade RJ
Fundam Clin Pharmacol; 2008 Apr; 22(2):141-58. PubMed ID: 18353109
[TBL] [Abstract][Full Text] [Related]
6. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method.
Rockey DC; Seeff LB; Rochon J; Freston J; Chalasani N; Bonacini M; Fontana RJ; Hayashi PH;
Hepatology; 2010 Jun; 51(6):2117-26. PubMed ID: 20512999
[TBL] [Abstract][Full Text] [Related]
7. Drug-induced liver injury and drug development: industry perspective.
Regev A
Semin Liver Dis; 2014 May; 34(2):227-39. PubMed ID: 24879986
[TBL] [Abstract][Full Text] [Related]
8. Drug Induced Liver Injury: Can Biomarkers Assist RUCAM in Causality Assessment?
Teschke R; Schulze J; Eickhoff A; Danan G
Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28398242
[TBL] [Abstract][Full Text] [Related]
9. Advances in Idiosyncratic Drug-Induced Liver Injury Issues: New Clinical and Mechanistic Analysis Due to Roussel Uclaf Causality Assessment Method Use.
Teschke R; Danan G
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446036
[TBL] [Abstract][Full Text] [Related]
10. How to Diagnose and Exclude Drug-Induced Liver Injury.
Watkins PB
Dig Dis; 2015; 33(4):472-6. PubMed ID: 26159261
[TBL] [Abstract][Full Text] [Related]
11. Liver Injury in COVID-19 Patients with Drugs as Causatives: A Systematic Review of 996 DILI Cases Published 2020/2021 Based on RUCAM as Causality Assessment Method.
Teschke R; Méndez-Sánchez N; Eickhoff A
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563242
[TBL] [Abstract][Full Text] [Related]
12. Avoidability of drug-induced liver injury (DILI) in an elderly hospital cohort with cases assessed for causality by the updated RUCAM score.
Danjuma MI; Almasri H; Alshokri S; Khir FK; Elmalik A; Battikh NG; Abdallah IMH; Elshafei M; Fatima H; Mohamed MFH; Maghoub Y; Hussain T; Kamal I; Anwer Z; Bidmos MA; Elzouki AN
BMC Geriatr; 2020 Sep; 20(1):346. PubMed ID: 32928134
[TBL] [Abstract][Full Text] [Related]
13. Causality assessment in drug-induced liver injury.
Hayashi PH
Semin Liver Dis; 2009 Nov; 29(4):348-56. PubMed ID: 19826968
[TBL] [Abstract][Full Text] [Related]
14. A detection algorithm for drug-induced liver injury in medical information databases using the Japanese diagnostic scale and its comparison with the Council for International Organizations of Medical Sciences/the Roussel Uclaf Causality Assessment Method scale.
Hanatani T; Sai K; Tohkin M; Segawa K; Kimura M; Hori K; Kawakami J; Saito Y
Pharmacoepidemiol Drug Saf; 2014 Sep; 23(9):984-8. PubMed ID: 24596340
[TBL] [Abstract][Full Text] [Related]
15. RUCAM in Drug and Herb Induced Liver Injury: The Update.
Danan G; Teschke R
Int J Mol Sci; 2015 Dec; 17(1):. PubMed ID: 26712744
[TBL] [Abstract][Full Text] [Related]
16. Agreement Among Different Scales for Causality Assessment in Drug-Induced Liver Injury.
Das S; Behera SK; Xavier AS; Velupula S; Dkhar SA; Selvarajan S
Clin Drug Investig; 2018 Mar; 38(3):211-218. PubMed ID: 29185238
[TBL] [Abstract][Full Text] [Related]
17. Drug-Induced Liver Injury Network Causality Assessment: Criteria and Experience in the United States.
Hayashi PH
Int J Mol Sci; 2016 Feb; 17(2):201. PubMed ID: 26861284
[TBL] [Abstract][Full Text] [Related]
18. Causality assessment methods in drug induced liver injury: strengths and weaknesses.
García-Cortés M; Stephens C; Lucena MI; Fernández-Castañer A; Andrade RJ
J Hepatol; 2011 Sep; 55(3):683-691. PubMed ID: 21349301
[TBL] [Abstract][Full Text] [Related]
19. Preliminary Results of a Novel Algorithmic Method Aiming to Support Initial Causality Assessment of Routine Pharmacovigilance Case Reports for Medication-Induced Liver Injury: The PV-RUCAM.
Scalfaro E; Streefkerk HJ; Merz M; Meier C; Lewis D
Drug Saf; 2017 Aug; 40(8):715-727. PubMed ID: 28508325
[TBL] [Abstract][Full Text] [Related]
20. Idiosyncratic Drug-Induced Liver Injury (DILI) and Herb-Induced Liver Injury (HILI): Diagnostic Algorithm Based on the Quantitative Roussel Uclaf Causality Assessment Method (RUCAM).
Teschke R; Danan G
Diagnostics (Basel); 2021 Mar; 11(3):. PubMed ID: 33800917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
